Literature DB >> 12848472

The current management strategies for community-acquired urinary tract infection.

Thomas M Hooton1.   

Abstract

Acute uncomplicated UTI is one of the most common problems for which young women seek medical attention and accounts for considerable morbidity and health care costs. Acute cystitis or pyelonephritis in the adult patient should be considered uncomplicated if the patient is not pregnant or elderly, if there has been no recent instrumentation or antimicrobial treatment, and if there are no known functional or anatomic abnormalities of the genitourinary tract. Most of these infections are caused by E. coli, which are susceptible to many oral antimicrobials, although resistance is increasing to some of the commonly used agents, especially TMP-SMX. In women with risk factors for infection with resistant bacteria, or in the setting of a high prevalence of TMP-SMX-resistant uropathogens, a case can be made for using a fluoroquinolone or nitrofurantoin. Use of nitrofurantoin for the empiric treatment of mild cystitis is supportable from a public health perspective in an attempt to decrease uropathogen resistance because it does not share cross-resistance with more commonly prescribed antimicrobials. Beta-lactams and fosfomycin should be considered second-line agents for empiric treatment of cystitis. Acute pyelonephritis in an otherwise healthy woman may be considered an uncomplicated infection. Fluoroquinolone regimens are superior to TMP-SMX for empiric therapy because of the relatively high prevalence of TMP-SMX resistance among uropathogens causing pyelonephritis. TMP-SMX, effective for patients with mild to moderate disease, is an appropriate drug if the uropathogen is known to be susceptible. It is reasonable to use a 7- to 10-day oral fluoroquinolone regimen for outpatient management of mild to moderate pyelonephritis in the setting of a susceptible causative pathogen and rapid clinical response to therapy. Most women with acute uncomplicated pyelonephritis are now managed safely and effectively as outpatients. Acute uncomplicated cystitis or pyelonephritis in healthy adult men is very uncommon but is generally caused by the same spectrum of uropathogens with the same antimicrobial susceptibility profile as that seen in women. The choice of antimicrobials is similar to that recommended for cystitis in women except that nitrofurantoin is not considered a good choice. Treatment duration should generally be longer than that recommended for women.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848472     DOI: 10.1016/s0891-5520(03)00004-7

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  22 in total

1.  Risk factors for infection and colonization with community-associated methicillin-resistant Staphylococcus aureus in the Los Angeles County jail: a case-control study.

Authors:  Cynthia L Maree; Samantha J Eells; Jennifer Tan; Elizabeth A Bancroft; Mark Malek; Nina T Harawa; Martha J Lewis; Elaine Santana; Loren G Miller
Journal:  Clin Infect Dis       Date:  2010-10-29       Impact factor: 9.079

2.  The potential impact of biomarker-guided triage decisions for patients with urinary tract infections.

Authors:  A Litke; R Bossart; K Regez; U Schild; M Guglielmetti; A Conca; P Schäfer; B Reutlinger; B Mueller; W C Albrich
Journal:  Infection       Date:  2013-02-24       Impact factor: 3.553

Review 3.  Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy.

Authors:  Patricia Brown; Moran Ki; Betsy Foxman
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Is 5 days of oral fluoroquinolone enough for acute uncomplicated pyelonephritis? The DTP randomized trial.

Authors:  A Dinh; B Davido; M Etienne; F Bouchand; A Raynaud-Lambinet; E Aslangul-Castier; T A Szwebel; C Duran; G Der Sahakian; C Jordy; X Ranchoux; N Sembach; E Mathieu; A Davido; J Salomon; L Bernard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-10       Impact factor: 3.267

5.  Antimicrobial Selection in the Treatment of Pyelonephritis.

Authors:  Patricia D Brown
Journal:  Curr Infect Dis Rep       Date:  2004-12       Impact factor: 3.725

6.  Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.

Authors:  Patricia Komp Lindgren; Linda L Marcusson; Dorthe Sandvang; Niels Frimodt-Møller; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Clonal composition of Escherichia coli causing community-acquired urinary tract infections in the State of Rio de Janeiro, Brazil.

Authors:  Rubens C S Dias; Denise V Marangoni; Sherry P Smith; Elizabeth M Alves; Flavia L P C Pellegrino; Lee W Riley; Beatriz M Moreira
Journal:  Microb Drug Resist       Date:  2009-12       Impact factor: 3.431

Review 8.  Contemporary management of uncomplicated urinary tract infections.

Authors:  David R P Guay
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Crystal structures of Klebsiella pneumoniae dihydrofolate reductase bound to propargyl-linked antifolates reveal features for potency and selectivity.

Authors:  Kristen M Lamb; Michael N Lombardo; Jeremy Alverson; Nigel D Priestley; Dennis L Wright; Amy C Anderson
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

10.  Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days).

Authors:  Cees van Nieuwkoop; Jan W van't Wout; Willem J J Assendelft; Henk W Elzevier; Eliane M S Leyten; Ted Koster; G Hanke Wattel-Louis; Nathalie M Delfos; Hans C Ablij; Ed J Kuijper; Jan Pander; Jeanet W Blom; Ida C Spelt; Jaap T van Dissel
Journal:  BMC Infect Dis       Date:  2009-08-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.